Diabetes Mellitus Clinical Trial
— DASHOfficial title:
Improving Health Self-Management Using Walking Biobehavioral Intervention for People With Dysvascular Lower Limb Amputation
The purpose of this study is to determine if walking biobehavioral intervention improves physical activity after dysvascular lower limb amputation.
Status | Recruiting |
Enrollment | 64 |
Est. completion date | January 1, 2026 |
Est. primary completion date | January 1, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years to 85 Years |
Eligibility | Inclusion Criteria: - Within the age range of 50-85 years - Confirmed diagnosis of Type II Diabetes Mellitus (DM) and/or Peripheral Artery Disease (PAD) - Transtibial, knee disarticulation, or transfemoral lower-limb amputation (LLA) (or re-amputation) within the past 12 months - Participant goal of household walking or better using a prosthesis Exclusion Criteria: - Trauma or cancer-related etiology of the LLA - Decisionally challenged individuals (MMSE score below 24) - Prisoners - Active cancer treatment - Recent stroke (within 2 years) - Clinical discretion of principal investigator to exclude patients who are determined to be unsafe and/or inappropriate to participate in the described intervention. |
Country | Name | City | State |
---|---|---|---|
United States | University of Colorado Hospital | Aurora | Colorado |
Lead Sponsor | Collaborator |
---|---|
University of Colorado, Denver | National Institute of Nursing Research (NINR) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Activities-specific Balance Confidence Scale | Change in self-reported balance confidence. Final scores range from 0% (no confidence in balance) to 100% (complete confidence in balance). | Day 0, 3 months, 6 months and 12 months | |
Other | Two-Minute Walk Test | Change in the distance a participant can walk in two minutes. Use of assistive device is noted | Day 0, 3 months, 6 months and 12 months | |
Other | Five Meter Walk | Change in the length of time it takes a participant to walk 5 meters, at a comfortable walking pace. | Day 0, 3 months, 6 months and 12 months | |
Other | Study Intervention Reach | Percentage of eligible participants enrolled | Day 0 | |
Other | Outpatient Practitioner Intervention Fidelity | An individual practitioner's percent adherence to outpatient intervention protocol | Day 0 through 3 months | |
Other | Biobehavioral Practitioner Intervention Fidelity | An individual interventionist's percent adherence to biobehavioral intervention protocol | Day 0 through 6 months | |
Other | FitBit Use Adherence | Number of days participant uses FitBit during the no-contact phase of the study | Month 12 | |
Primary | Physical Activity | Change in 10 day physical activity step count with ActivPAL activity monitor between the beginning of conventional prosthetic rehabilitation to the end of intervention. Maintenance will be observed at six months after the end of the intervention. | Day 0 (start of conventional prosthetic rehabilitation), prosthetic rehabilitation end (3 months), intervention end (6 months), and 6 months after intervention end (12 months) | |
Secondary | Patient Reported Outcomes Measurement Information System (PROMIS): Self-Efficacy for Managing Symptoms | Change in participant's confidence in managing symptoms of chronic disease. Final scores range from 4 points (not at all confident) to 20 points (very confident). | Day 0, 3 months, 6 months and 12 months | |
Secondary | PROMIS: Self-Efficacy for Managing Daily Activities | Change in participant's confidence in managing daily activities. Final scores range from 4 points (not at all confident) to 20 points (very confident). | Day 0, 3 months, 6 months and 12 months | |
Secondary | PROMIS: Ability to participate in social roles and activities | Change in participant's ability to participate in social roles and activities. Final scores range from 8 points (never participates) to 40 points (always participates). | Day 0, 3 months, 6 months and 12 months | |
Secondary | Prosthesis Evaluation Questionnaire - Mobility Score | Change in self-reported mobility. Final scores range from 0 (lowest mobility) to 4 (highest mobility) | Day 0, 3 months, 6 months and 12 months | |
Secondary | Timed Up-and-Go test | Change in time required to rise from chair, walk 10 feet, turn around and return to sitting in same chair. | Day 0, 3 months, 6 months and 12 months | |
Secondary | World Health Organization-Disability Assessment Schedule 2.0 | Change in self-reported disability. Final scores range from 0 (no disability) to 100 (full disability). | Day 0, 3 months, 6 months and 12 months | |
Secondary | Self-Efficacy for Managing Chronic Disease | Change in self-reported confidence in managing different aspects of chronic disease. Final scores range from 1 (not at all confident in managing chronic disease) to 10 (totally confident in managing chronic disease). | Day 0, 3 months, 6 months and 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |